Janus kinase (JAK) inhibitors are immunomodulatory agents with broad potential for use
within dermatology. However, the US Food and Drug Administration has recently placed …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Janus kinase inhibitors, also commonly referred to as JAK inhibitors, are a novel drug class
that target and block cytokine signaling mediated by the Janus kinase-signal transducer and …

Importance Janus kinase (JAK) inhibitors are an effective treatment option for patients with
certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but …

JAK inhibitors target specific inflammatory cytokines involved in various inflammatory
diseases. Four molecules have been approved for dermatological use: upadacitinib …

The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway
is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti …

Considerable controversy related to the cardiovascular safety of Janus kinase inhibitors
(JAKinibs) has arisen following the results of the ORAL Surveillance trial. In this trial of …

The class of medications known as Janus kinase inhibitors block cytokine-mediated
signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) …

Background Janus kinase (JAK) inhibitors are emerging as a promising new treatment
modality for many inflammatory conditions. Objective Our aim was to systematically review …

Background Janus kinase (JAK) inhibitors have attracted attention for their role in treating
inflammatory disorders. This new class of biologics has the potential to significantly affect the …